Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

(2012) Christian Confavreux et al.   Multiple Sclerosis Journal

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

(2010) V. Devonshire et al.   EUROPEAN JOURNAL OF NEUROLOGY

Fatigue Impact Scale

(2010) J. Frith et al.   OCCUPATIONAL MEDICINE-OXFORD

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

(2009) Jean E. Merrill et al.   JOURNAL OF NEUROLOGY